Trending...
- Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
- Boston: Inaugural Cohort of Young Black Leaders Announced
- See what our March partners are offering now!
Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.
Dragonfly to receive a $25 million payment and is eligible to receive potential future milestones and royalties on net sales.
WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.
"We are delighted that our research collaboration initiated with Dragonfly in July 2020 on multiple sclerosis and neuro-inflammation has rapidly produced novel TriNKET drug candidate molecules that may provide new treatment options for patients with neurological diseases" said Richard Hargreaves, Senior Vice President, Neuroscience, Bristol Myers Squibb.
More on Boston Chron
"We believe this opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly's CEO. "The ongoing clinical trials of six Dragonfly-developed drugs including our wholly owned solid tumor targeting TriNKETs DF1001 (HER2), now in Phase 2, DF9001 (EGFR), and our BMS-partnered novel IL12 cytokine, underscore the breadth of Dragonfly's portfolio of innovative therapeutics, and potential to help patients with hematological cancers, solid tumor cancers, autoimmune diseases, and neurological conditions."
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:
www.dragonflytx.com
More on Boston Chron
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck | [email protected]
Logo - https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Inc_Logo.jpg
SOURCE Dragonfly Therapeutics, Inc.
Dragonfly to receive a $25 million payment and is eligible to receive potential future milestones and royalties on net sales.
WALTHAM, Mass., Jan. 6, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today's announcement marks the first TriNKET opt-in outside of oncology.
"We are delighted that our research collaboration initiated with Dragonfly in July 2020 on multiple sclerosis and neuro-inflammation has rapidly produced novel TriNKET drug candidate molecules that may provide new treatment options for patients with neurological diseases" said Richard Hargreaves, Senior Vice President, Neuroscience, Bristol Myers Squibb.
More on Boston Chron
- Boston: March 2023: Latest Updates from the Mayor's Office of Housing
- Boston: April Allston/Brighton Community Center Study Meeting
- Boston: Mayor Wu Launches $750,000 Grant Fund to Support Growth of Businesses and Access to City Contracts
- Mayor Wu Announces $4 Million Investment to Expand Boston's Tuition Free Community College Program
- Boston: Meet the Fine Arts Work Center Scholarship Recipients
"We believe this opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly's CEO. "The ongoing clinical trials of six Dragonfly-developed drugs including our wholly owned solid tumor targeting TriNKETs DF1001 (HER2), now in Phase 2, DF9001 (EGFR), and our BMS-partnered novel IL12 cytokine, underscore the breadth of Dragonfly's portfolio of innovative therapeutics, and potential to help patients with hematological cancers, solid tumor cancers, autoimmune diseases, and neurological conditions."
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:
www.dragonflytx.com
More on Boston Chron
- Boston: The Mary Eliza Project: Ward 3 Voter Records Now Available
- Boston AIR Spotlight: Ellice Patterson and Boston Transportation Department
- Mayor Wu Announces Applications Open for the 2023-2024 SPARK Boston Council
- Awake! Ye Sisters All: Sisterhood in Boston's Women's Voter Registers
- Mayor Wu Announces Events in Remembrance of the 2013 Boston Marathon
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck | [email protected]
Logo - https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Inc_Logo.jpg
SOURCE Dragonfly Therapeutics, Inc.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Olga Torres Named Top Advisor by Foreign Investment Watch
- Benchmark International Scsflly Fclitd The Trnstn Btw Bagel King Wholesale and Austin Circle Partner
- Attorney Steve Hilst Named Partner at Bisnar Chase
- 26 Provider Fairview Community Health Center Transitions to Intelligent eClinicalWorks Cloud
- New xBit Digital Case Management Feature Saves Examiners Hours of Required Report Upload Time
- Knobull Helps Professionals Fight Personal Isolation At School & Work
- IntellaTriage Hires New Vice President of Technology
- ASI Hosts 2023 Executive Summit for Partners and Announces Annual Award Winners
- Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
- Namify's Website Name Generator: The Ultimate Solution for Finding Your Perfect Website Name
- NFL Quarterback Lamar Jackson & Lamar Jackson Entertainment Presents Roll With The Punches 'It's Okay Knot To Be Okay' Black Tie & Sneaker Gala
- Tuani Lash Brings Luxury Lash Services and Joy to Oakland's Homeless Community
- Massachusetts: Governor Healey Signs $389 Million Supplemental Budget
- Sherry Orel Joins STS Capital Partners
- Boston: City Council Recognizes International Cape Verdean Women's Day
- American Equus Expands Product Line with Suomy Riding Helmets
- "Third Thursdays": w/former Ornette Coleman colleagues joining host Dave Bryant in April & May 2023
- Arbutus Medical Launches TrakPak® with QuikBow™ to Improve Skeletal Traction, Announces Successful Cases
- Axis Communications Unveils New Devices at ISC West, Underscoring Its Commitment to Deep Learning and Advanced Analytics
- Healey-Driscoll Administration Announces Funding for 450 New Affordable Housing Units Across Massachusetts